PRPO (Precipio) Quality Rank

View and export this data going back to 2000. Start your Free Trial

What is Precipio Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Precipio Quality Rank Related Terms

Thank you for viewing the detailed overview of Precipio's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Precipio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Precipio Inc (NAS:PRPO) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Science Park, New Haven, CT, USA, 06511

Website

https://www.precipiodx.com

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Executives

Richard A Sandberg	director	330 NEVEDA STREET, NEWTON MA 02460-1458
Ahmed Zaki Sabet	officer: Chief Operations Officer	33 ANDYS DR, EAST HAVEN CT 06512
Ilan Danieli	director, officer: Chief Executive Officer	14707 CALIFORNIA STREET, SUITE 5, OMAHA NE 68154
Matthew Gage	officer: Chief Financial Officer	56 STAGECOACH CIRCLE, MILFORD CT 06460
David Seth Cohen	director, 10 percent owner	C/O STANDARD OIL, 299 BISHOP AVENUE, BRIDGEPORT CT 06610
Ronald Asbury Andrews	director	5791 VAN ALLEN WAY, CARLSBAD CA 92008
Randal J Kirk	10 percent owner	1881 GROVE AVENUE, RADFORD VA 24141
Kathleen Laporte	director
Robert Patzig	director	THE GOVERNOR TYLER, 1881 GROVE AVENUE, RADFORD VA 24141
Michael A Luther	director	21 CORPORATE CIRCLE, ALBANY NY 12203
Jeffrey Cossman	director	C/O PRECIPIO INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Samuel D Riccitelli	director	2850 FRONTIER DR., WARSAW IN 46582
Carl Iberger	officer: Chief Financial Officer	C/O PRECIPIO, INC., 12325 EMMET STREET, OMAHA NE 68164
Douglas Fisher	director	587 PATROL RD, WOODSIDE CA 94062
Mark Rimer	director, 10 percent owner	C/O PRECIPIO, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511